In our multiple regression models, we were able to show that the five antibodies against AT1-receptor, PAR1, VEGF-A, VEGF-B, and VEGF-receptor 2 cannot predict clinical activity parameters for nAMD, like the number of injections, development of intra- or subretinal fluid, macular bleeding, and development of fibrosis. Here, VEGFB is linked to fibrosis.